Leading The Charge On US Humira Competition, Organon Sets Out Strategy
US Biosimilars Head Jon Martin Talks Adalimumab And Further Opportunities Beyond
With US biosimilar competition to Humira slow to start in 2023, Organon’s US biosimilars head Jon Martin talks about how the firm is pushing forward to ramp up progress on adalimumab this year, as well as longer-term opportunities.
